Bilal Jalil, MD
Critical Care Medicine · Waxahachie, TXNPI 1982044723
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. GE HealthCare accounts for 69.1% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2020 at $6,874 and has fallen 96.1% since, to $271 in 2024. Among critical care medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $102.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$8K
- Actelion Pharmaceuticals US, Inc.$572
- Regeneron Healthcare Solutions, Inc.$491
- Samsung Medison Co., Ltd.$450
- Insmed, Inc.$282
- Boehringer Ingelheim$262
- plus $2K from 16 others
What the payments were for
- Consulting fees$1,95016%
- Speaking & faculty fees$4,94542%
- Travel & lodging$1,42112%
- Food & beverage$3,15027%
- Education$1892%
- Gifts$1812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 12 | $8,181 |
| Actelion Pharmaceuticals US, Inc. | 12 | $572 |
| Regeneron Healthcare Solutions, Inc. | 8 | $491 |
| Samsung Medison Co., Ltd. | 1 | $450 |
| Insmed, Inc. | 3 | $282 |
| Boehringer Ingelheim | 9 | $262 |
| Sanofi | 5 | $224 |
| AstraZeneca | 14 | $218 |
| GSK | 15 | $214 |
| United Therapeutics Corporation | 8 | $213 |
| Grifols USA, LLC | 1 | $151 |
| Genentech USA, Inc. | 2 | $112 |
| Electromed, Inc. | 5 | $78 |
| Mylan Specialty L.p. | 4 | $69 |
| Johnson & Johnson(2 entities) | 2 | $66 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
| Philips North America LLC | 2 | $40 |
| Nabriva Therapeutics, PLC | 2 | $34 |
| Novartis | 2 | $32 |
| Gilead | 2 | $30 |
| Merck | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,837 in reported general payments places this provider in the 90th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Furosemide | 12 | $28 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Waxahachie
- Steven DavidoffPlano$364K
- William BartekAustin$284K
- Edwin ParsleyHouston$283K
- Hector PayanEl Paso$245K
- Bindu AkkantiHouston$185K
- Faisal MasudHouston$155K
- Sergio Trevino CastilloHouston$133K
- Akinyinka AjelabiKingwood$109K
- Anthony OrtegonDallas$106K
- Gary WeinsteinDallas$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.